Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing. Phase 1 studies demonstrated greater bioavailability to twice-daily tacrolimus capsules and no new safety concerns. METHODS: In this phase 2 study, adult stable kidney transplant patients on tacrolimus capsules (Prograf) twice-daily were converted to tacrolimus tablets (LCP-Tacro) once-daily; patients continued on LCP-Tacro once-daily for days 8 to 21; trough levels were to be maintained between 5 and 15 ng/mL; 24-hr pharmacokinetic assessments were done on days 7 (baseline pre-switch), 14, and 21. RESULTS: Forty-seven patients completed LCP-Tacro dosing per protocol. The mean conversion ratio was 0.71. Pharmacokinetic data demonstrated consistent exposure (AUC) at the lower conversion dose. C(max) (P = 0.0001), C(max)/C(min) ratio (P < 0.001), percent fluctuation (P < 0.0001), and swing (P = 0.0004) were significantly lower and T(max) significantly (P < 0.001) longer for LCP-Tacro versus Prograf. AUC24 and C(min) correlation coefficients after 7 and 14 days of therapy were 0.86 or more, demonstrating a robust correlation between LCP-Tacro tacrolimus exposure and trough levels. There were three serious adverse events; none were related to study drug and all were resolved. CONCLUSIONS: Stable kidney transplant patients can be safely converted from Prograf twice-daily to LCP-Tacro. The greater bioavailability of LCP-Tacro allows for once-daily dosing and similar (AUC) exposure at a dose approximately 30% less than the total daily dose of Prograf. LCP-Tacro displays flatter kinetics characterized by significantly lower peak-trough fluctuations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although exhibiting prolonged absorption and multicompartmental pharmacokinetics, t1/2eff has not previously been explored for tacrolimus from LCPT.6,10”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LCPT presents a proprietary MeltDose technology that enhances oral bioavailability through a process known as “controlled agglomeration”.6,7”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The current study, which is the first to estimate the t1/2z for LCPT in adult kidney transplant recipients, approximated t1/2z at 20 hours compared with previous studies in healthy volunteers, where t1/2z estimates were reported to be approximately 31 hours.6,10”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990 · cited 1×
“This may partially account for lower troughs and higher dose requirements of tacrolimus among blacks (16).”
BackgroundThe Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance
Eisen, S. A. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.9.1881 · Cited by 817
Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review
Kripalani, S., Yao, X., & Haynes, R. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.6.540 · Cited by 810 · cited 1×
“In a review of medication adherence in chronic conditions, the most effective interventions appear to be those that simplify dosing demands (27, 28).”
BackgroundWallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468 · cited 2×
“tacrolimus trough blood concentrations are measured to ensure efficacy and safety (3).”
Background(2009) · PubMed · Cited by 359
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
OPTN/SRTR 2011 Annual Data Report: Kidney
Matas, A. J., Smith, J. M., Skeans, M. A., Lamb, K. E., Gustafson, S. K., Samana, C. J., Stewart, D. E., Snyder, J. J., Israni, A. K., & Kasiske, B. L. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12019 · Cited by 308 · cited 2×
“Tacrolimus is one of the most widely used immunosuppression drugs in kidney transplantation (1).”
Background
Cited by
Tremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., & Alloway, R. R. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13935 · Cited by 171
“LCPT is also associated with less fluctuation between maximum (“peak”) exposure and trough and with a lower peak exposure level (18).”
BackgroundResultInfluentialSelf-citationNelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Langone, A., Steinberg, S. M., Gedaly, R., Chan, L. K., Shah, T., Sethi, K. D., Nigro, V., Morgan, J. C., & STRATO Investigators (2015) · Clinical Transplantation · doi:10.1111/ctr.12581 · Cited by 119
“The PK profile of LCP-Tacro reveals a reduction in the peak-to-trough ratio and Cmax yet prolongs the Tmax of LCP-Tacro compared to twice-daily tacrolimus (18, 22).”
BackgroundRostaing, L. P. E., Bunnapradist, S., Grinyo, J. M., Ciechanowski, K., Denny, J. E., Junior, H. T. S., Budde, K., Denny, J. E., Kulkarni, S., Hricik, D. E., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.024 · Cited by 115
Self-citationWhalen, H. R., Glen, J. A., Harkins, V., Stevens, K., Jardine, A. G., Geddes, C., & Clancy, M. J. (2016) · Transplantation · doi:10.1097/tp.0000000000001129 · Cited by 105
Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients
Staatz, C. E., & Tett, S. E. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0282-2 · Cited by 101
Alloway, R. R., Eckhoff, D. E., Washburn, W. K., & Teperman, L. W. (2014) · Liver Transplantation · doi:10.1002/lt.23844 · Cited by 57
“LCP-Tacro demonstrated greater tacrolimus bioavailability and similar exposure [area under the curve (AUC)] at a dose approximately 30% less than the TTD of Prograf as well as significantly less fluctuation and swing in comparison with Prograf in stable kidney transplant recipients converted to LCP-Tacro.(16) The effi…”
BackgroundInfluentialSelf-citationTacrolimus for the prevention and treatment of rejection of solid organ transplants
Scalea, J. R., Levi, S. T., Ally, W. A., & Brayman, K. L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1123093 · Cited by 56
“Prograf®).[33,34] The potentially lower required dosing, lower peak values, and ‘flatter’ kinetic profile of extended-release formulations may lead to”
BackgroundWoillard, J., Debord, J., Monchaud, C., Saint‐Marcoux, F., & Marquet, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0533-5 · Cited by 50
“The PK profiles obtained using this new formulation exhibit comparable inter-individual variability with the one reported for Prograf in the original study reports [7, 8].”
MethodGrinyo, J. M., & Petruzzelli, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.983903 · Cited by 45
“Study 2011 was a Phase II, open-label, multicenter, prospective, conversion study in stable kidney transplant patients who were on a stable dose of twice-daily tacrolimus capsules, with trough levels of tacrolimus maintained at 7–12 ng/ml for at least 2 weeks before enrollment [35].”
BackgroundMethodInfluentialTacrolimus—why pharmacokinetics matter in the clinic
Henkel, L., Jehn, U., Thölking, G., & Reuter, S. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1160752 · Cited by 45
Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives
Oberbauer, R. W., Bestard, O., Furian, L., Maggiore, U., Pascual, J., Rostaing, L. P. E., & Budde, K. (2020) · Transplantation Reviews · doi:10.1016/j.trre.2020.100531 · Cited by 42
Garnock-Jones, K. P. (2015) · Drugs · doi:10.1007/s40265-015-0349-2 · Cited by 39
Influence of tacrolimus metabolism rate on renal function after solid organ transplantation
Thölking, G., Gerth, H. U., Schuette-Nuetgen, K., & Reuter, S. (2017) · World Journal of Transplantation · doi:10.5500/wjt.v7.i1.26 · Cited by 36
Xu, H., Liu, L., Li, X., Ma, J., Liu, R., & Wang, S. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.08.001 · Cited by 36
Bunnapradist, S., Rostaing, L. P. E., Alloway, R. R., West‐Thielke, P. M., Denny, J. E., Mulgaonkar, S. P., & Budde, K. (2016) · Transplant International · doi:10.1111/tri.12770 · Cited by 38
Self-citationEmerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation
Wong, T. C.-L., Lo, C., & Fung, J. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1330884 · Cited by 35
“Hence, LCP-tacrolimus has a more favorable pharmacokinetic (PK) profile compared to conventional tacrolimus [59,60], achieving the same drug exposure with 30% less dose.”
BackgroundImmunosuppressive drugs and the gastrointestinal tract in renal transplant patients
Tielemans, M. M., van Boekel, G. A. J., van Gelder, T., Tjwa, E. T. T. L., & Hilbrands, L. B. (2018) · Transplantation Reviews · doi:10.1016/j.trre.2018.11.001 · Cited by 31
Overview of extended release tacrolimus in solid organ transplantation
Patel, N., Cook, A. L., Greenhalgh, E., Rech, M. A., Rusinak, J., & Heinrich, L. S. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i1.144 · Cited by 30
Update on the clinical utility of once-daily tacrolimus in the management of transplantation
Salas, M. A. P., & Srinivas, T. R. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55458 · Cited by 27
“The greater bioavailability of once-daily tacrolimus allowed similar AUC exposure using a dose that is about 30% lower than the twice-daily formulation.(9,10) Among pediatric kidney transplant recipients, AUC and trough were noted to decrease after conversion to once-daily tacrolimus.”
Meltdose Tacrolimus Pharmacokinetics
Baraldo, M. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.02.002 · Cited by 27
Sánchez-Fructuoso, A. I., Ruiz, J. C., Franco, A., Diekmann, F., Redondo‐Pachón, D., Calviño, J., Serra, N., Aladrén, M. J., Cigarrán, S., Manonelles, A., et al. (2019) · Clinical Transplantation · doi:10.1111/ctr.13767 · Cited by 25
Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations
Tremblay, S., & Alloway, R. R. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0119-z · Cited by 27
Self-citationTremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature
Shukla, A. W., Lunny, C., Mahboob, O., Khalid, U., Joyce, M., Jha, N., Nagaraja, N., & Shukla, A. M. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00428-4 · Cited by 20
“Once-daily extended-release formulation has about a 30% greater relative bioavailability, about a 30% lower peak-to-trough fluctuation, and a consistently lower daily dose than prolonged-release tacrolimus [63, 96–98].”
BackgroundGustavsen, M. T., Midtvedt, K., Robertsen, I., Woillard, J., Debord, J., Klaasen, R. A., Vethe, N. T., Bergan, S., & Åsberg, A. (2020) · Clinical and Translational Science · doi:10.1111/cts.12833 · Cited by 19
Bunthof, K. L. W., Al‐Hassany, L., Nakshbandi, G., Hesselink, D. A., van Schaik, R. H. N., ten Dam, M. A. G. J., Baas, M. C., Hilbrands, L. B., & van Gelder, T. (2021) · Clinical and Translational Science · doi:10.1111/cts.13206 · Cited by 18
King, C. P., Cossart, A. R., Isbel, N. M., Campbell, S. B., & Staatz, C. E. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100815 · Cited by 18
Rivera, C. F., Rodríguez, M. C., Poveda, J. L., Pascual, J., Crespo, M., Gómez, G., Pelegrin, S. C., Paúl, J., Lauzurica, R., Pérez‐Mir, M., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14550 · Cited by 18
Giral, M., Grimbert, P., Morin, B., Bouvier, N., Büchler, M., Dantal, J., Garrigue, V., Bertrand, D., Kamar, N., Malvezzi, P., et al. (2024) · Transplant International · doi:10.3389/ti.2024.11571 · Cited by 19
“More severe CNI-related toxicities have been reported with a higher CNI C max [24, 28]; this may explain why the TETRAS scores in this study improved following the switch to LCPT, which has a consistently lower C max than all other tacrolimus formulations [14].”
InfluentialDuBay, D. A., Teperman, L. W., Ueda, K., Silverman, A., Chapman, W. C., Alsina, A. E., Tyler, C., & Stevens, D. R. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.657 · Cited by 17
Vadcharavivad, S., Saengram, W., Phupradit, A., Poolsup, N., & Chancharoenthana, W. (2019) · Drugs · doi:10.1007/s40265-019-01217-7 · Cited by 20
Hénin, É., Govoni, M., Cella, M., Laveille, C., & Piotti, G. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01905-5 · Cited by 16
Extended release once a day tacrolimus
Singh, N. K., Visger, J. R. V., & Zachariah, M. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000251 · Cited by 15
“The drug also displays flatter kinetics characterized by significantly lower peak-trough fluctuations [43] and may result in less peak-related toxicity.”
BackgroundSpagnoletti, G., Gargiulo, A., Salerno, M. P., Favi, E., Pedroso, J. A. R., Calia, R., Romagnoli, J., & Citterio, F. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.08.003 · Cited by 15
Fontova, P., Colom, H., Rigo-Bonnin, R. F., Bestard, O., Vidal‐Alabró, A., van Merendonk, L. N., Cerezo, G., Polo, C., Montero, N., Melilli, E., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2220 · Cited by 14
“As expected, PK profiles obtained in our study were in accordance with previous studies.(7,31,32) A higher fluctuating profile during dose intervals was observed after TacIR due to the large differences in the absorption/elimination rate.”
ResultSuwelack, B. M., Bunnapradist, S., Meier‐Kriesche, U., Stevens, D. R., Procaccianti, C., Morganti, R., & Budde, K. (2020) · Annals of Transplantation · doi:10.12659/aot.923278 · Cited by 13
Self-citationJouvé, T., Rostaing, L. P. E., & Malvezzi, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1328051 · Cited by 14
“lower for Envarsus® compared to Prograf®, and the Tmax is significantly prolonged [45].”
Ali, Z. M., Meertens, M., Fernández, B., Fontova, P., Vidal‐Alabró, A., Rigo-Bonnin, R. F., Melilli, E., Cruzado, J. M., Grinyo, J. M., Colom, H., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122699 · Cited by 12
Genomics in CKD: Is This the Path Forward?
Nadkarni, G. N., & Horowitz, C. R. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.01.017 · Cited by 12
van Gelder, T., Etsouli, O., Moes, D. J. A. R., & Swen, J. J. (2020) · Genes · doi:10.3390/genes11101205 · Cited by 11
“For Envarsus®, it has been shown that, on average, the difference between trough and peak concentrations (referred to as peak-trough fluctuations) is smaller than for the immediate release formulation [22].”
BackgroundChoi, D., Thaker, S., West‐Thielke, P. M., Elmasri, A. F., & Chan, C. S. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002172 · Cited by 11
Torabi, J., Konicki, A., Rocca, J. P., Ajaimy, M., Campbell, A., Azzi, Y. A., Pynadath, C. T., Liriano-Ward, L. E., Akalin, E., Kinkhabwala, M. M., et al. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.02.027 · Cited by 11
Piotti, G., Cremaschi, E., & Maggiore, U. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0316-3 · Cited by 12
Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers
Alloway, R. R., Trofe-Clark, J., Brennan, D. C., Kerr, J., Cohen, E. A., Meier-Kriesche, U., Stevens, D. R., Moten, M. A., & Momper, J. D. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000773 · Cited by 10
Self-citationTang, T., Lü, Q., Yang, X. H., Liu, X., Liao, R., Zhang, Y., & Yang, Z. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.014 · Cited by 10
Mimura, A., Yamaori, S., Ikemura, N., Katsuyama, Y., Matsuzawa, N., & Ohmori, S. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12834 · Cited by 10
Update on the clinical utility of once-daily tacrolimus in the management of transplantation
Revollo, J. Y. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s84301 · Cited by 10
El‐Nahhas, T., Popoola, J., MacPhee, I. A. M., & Johnston, A. E. (2021) · Clinical and Translational Science · doi:10.1111/cts.12990 · Cited by 9
Improved Kidney Allograft Function after Early Conversion of Fast IR-Tac Metabolizers to LCP-Tac
Thölking, G., Tosun-Koç, F., Jehn, U., Koch, R., Pavenstädt, H. J., Suwelack, B. M., & Reuter, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051290 · Cited by 10
“Since the total exposure to the drug (area under the curve) and the trough level of fast and slow metabolizers and of LCPT and IR-Tac-treated patients are generally comparable, other factors—and it is probably not Tac metabolites that are similar in patients with low and high C/D ratios—must be responsible for the obs…”
BackgroundResultTan, T., & Bunnapradist, S. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1974399 · Cited by 9
Self-citationAltieri, M. H., Delaval, G., Kimmoun, E., Allaire, M., Salamé, E., & Dumortier, J. (2017) · Experimental and Clinical Transplantation · doi:10.6002/ect.2016.0328 · Cited by 9
The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function
Mahaparn, I., Lepping, R. J., Montgomery, R. N., Mukherjee, R., Billinger, S. A., Brooks, W. M., & Gupta, A. (2023) · Transplantation Direct · doi:10.1097/txd.0000000000001511 · Cited by 8
Yang, S., Choi, J. Y., Cho, W. T., Park, J. B., & Kim, S. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.12.042 · Cited by 8
January, S. E., Hagopian, J. C., Nesselhauf, N. M., Progar, K., Horwedel, T. A., & Santos, R. D. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00842-w · Cited by 8
Getting Tacrolimus Dosing Right
Marquet, P. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001266 · Cited by 8
Philosophe, B., Leca, N., West‐Thielke, P. M., Horwedel, T. A., Culkin‐Gemmell, C., Kistler, K. D., & Stevens, D. R. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1082 · Cited by 8
Sintes, H., Sáez, B., Berastegui, C., López‐Meseguer, M., Monforte, V., Bravo, C., Vima, J., Gómez‐Ollés, S., & Román, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002348 · Cited by 7
Envarsus, una novedad para los nefrólogos del trasplante: estudio observacional retrospectivo
Franco, A., Más‐Serrano, P., Balibrea, N., Rodríguez, D., Javaloyes, A., Díaz, M., Gascón, I., Ramón-López, A., Pérez-Contreras, J., Selva, J., et al. (2019) · Nefrología · doi:10.1016/j.nefro.2018.11.009 · Cited by 7
Envarsus, a novelty for transplant nephrologists: Observational retrospective study
Franco, A., Más‐Serrano, P., Balibrea, N., Rodríguez, D., Javaloyes, A., Díaz, M., Gascón, I., Ramón-López, A., Pérez-Contreras, J., Selva, J., et al. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.11.020 · Cited by 8
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome
Dohl, J., Treadwell, Z., Norris, C. M., & Head, E. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70034 · Cited by 7
Milone, M. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800885-0.00001-1 · Cited by 6
Sukkha, S., Chindavijak, B., Montakantikul, P., Ingsathit, A., Nosoongnoen, W., & Sumethkul, V. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0549-9 · Cited by 6
“Envarsus®, for example, a modified-release tacrolimus formulation, produced by Meldose drug technology, showed a supra-bioavailability compared with Advagraf®, a modified-release tacrolimus formulation produced by a matrix system [18, 21, 22].”
BackgroundRecent trials in immunosuppression and their consequences for current therapy
Wohlfahrtová, M., & Viklický, O. (2014) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000093 · Cited by 5
Torres, A., Adanero, C. R., Rivera, C. F., Miranda, D. M., Bonis, E. D., Hernández, A. R., Tamajón, L. P., González-Rinne, A. M., Sosa, D. Á., Álvarez-González, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247802 · Cited by 5
“Compared to IR-Tac and ER-Tac, LCPT has a lower and delayed peak with comparable minimum concentrations and less peak-to-trough fluctuation [11–15].”
Monchaud, C., Woillard, J., Crépin, S., Tafzi, N., Micallef, L., Rérolle, J.-P., Dharancy, S., Conti, F., Choukroun, G. J., Thierry, A., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11366 · Cited by 5
Immunosuppression strategies in elderly renal transplant recipients
Camilleri, B., Pararajasingam, R., Buttigieg, J., & Halawa, A. M. (2020) · Transplantation Reviews · doi:10.1016/j.trre.2020.100529 · Cited by 5
Chao, S., Jia, L., Zhu, K., Chen, L., & Niu, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226647 · Cited by 5
Rovira, J., Millán, O., Ventura‐Aguiar, P., Brunet, M., & Diekmann, F. (2025) · Pharmaceuticals · doi:10.3390/ph18101488 · Cited by 4
“The increased tacrolimus bioavailability from LCPT is associated with a significant lower Cmax [5] with a consistent tacrolimus exposure (AUC) at an approximately 30–36% lower dose compared to twice-daily (IR-TAC) 2,3 or 30% compared to PR-TAC [4], showing non-inferior efficacy and similar safety…”
Tacrolimus Intrapatient Variability as a Biomarker in Solid Organ Transplantation
Nogueiras‐Álvarez, R., & García-Saiz, M. D. M. (2025) · Clinical Transplantation · doi:10.1111/ctr.70197 · Cited by 4
“In this study, the TETRAS score (which stands for The Essential Tremor Rating Assessment Scale) improved after switching to an LCPT (that has lower C max than the other tacrolimus formulations) [79].”
Envarsus XR ® pharmacokinetics in adolescents post‐kidney transplantation – A pilot study
ElChaki, R., Ettenger, R. B., Lee, S., Chen, L., Gales, B., Srivastava, R., & Pearl, M. H. (2023) · Pediatric Transplantation · doi:10.1111/petr.14480 · Cited by 4
Diamond, A., Karhadkar, S. S., Chavin, K. D., Constantinescu, S., Lau, K. N., Perez-Leal, O., Mohrien, K. M., Sifontis, N. M., & Carlo, A. D. (2023) · World Journal of Transplantation · doi:10.5500/wjt.v13.i6.368 · Cited by 4
Yin, J. H., Hsu, T., Kerr, J., Steiner, R. W., & Awdishu, L. (2020) · Pharmacy · doi:10.3390/pharmacy8020060 · Cited by 4
Momper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001270 · Cited by 3
Hurwitz, J. T., Grizzle, A. J., Tyler, C., Zapata, L. V., & Malone, D. C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.948 · Cited by 3
Rațiu, I. A., Bănică, F., Moisa, C., Pașca, B., Gîtea, D., Grosu, I. D., Bako, G. C., Voștinaru, O., Dayyih, W. A., & Filip, L. A. (2025) · Pharmaceuticals · doi:10.3390/ph18101532 · Cited by 3
“To address this, a once-daily formulation was developed to enhance TAC absorption by creating a solid dispersion of the drug through a physical process known as controlled agglomeration [10].”
Martial, L. C., Verstegen, R. H. J., Cornelissen, E. A. M., Aarnoutse, R. E., Schreuder, M. F., & Brüggemann, R. J. M. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12639 · Cited by 3
Magid, M., Sanoff, S., Lee, H., Yang, Z., & Byrns, J. S. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211021054 · Cited by 3
Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy
Alhamad, T., Venkatachalam, K., Daloul, R., Brennan, D. C., & Malone, A. F. (2017) · Transplantation · doi:10.1097/tp.0000000000001797 · Cited by 3
“Tacrolimus-LCP (Tac-LCP) (Envarsus XR) is an extendedrelease once-daily tacrolimus preparation that has lower peak concentration, less fluctuation, similar trough levels, and similar exposure measured by area under the curve as twice daily immediate release tacrolimus (Tac-IR).(3) Langone et al(4) reported a statistic…”
MethodEarly Use of Tacrolimus Extended-Release in a Pediatric Kidney Transplant Recipient
Szempruch, K. R., Westreich, K. D., & Toledo, A. H. (2017) · Experimental and Clinical Transplantation · doi:10.6002/ect.2017.0195 · Cited by 3
Hidaka, Y., Goto, N., Yamanaga, S., Kinoshita, K., Tanaka, K., Kawabata, C., Toyoda, M., Tomosugi, T., Futamura, K., Okada, M., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14655 · Cited by 3
Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View
Lemaitre, F., Tron, C., & Rayar, M. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14237 · Cited by 3
“(2) have already explored the relationship between daily dose of TAC and exposure in 60 stable renal transplant recipients converted to LCPT and”
BackgroundLewis, T. C., Hotchkis, P., Wong, A., LaMaina, V., Fitzpatrick, E., Stiefel, A., Ohanian, J., Schnier, J., Lesko, M. B., Rudym, D., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70159 · Cited by 2
Herden, U., Sterneck, M. R., Buchholz, B. M., Achilles, E. G., Ott, A., & Fischer, L. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.537 · Cited by 2
Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1405070 · Cited by 2
Soliman, T., Györi, G., Salat, A., Mejzlík, V., & Berlakovich, G. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072537 · Cited by 2
“This once-daily formulation allows for less peak-to-trough fluctuation and, consequently, better controllability of drug dosing [14].”
BackgroundExtended-release tacrolimus tablets for preventing organ transplant rejection
Horwedel, T. A., & Brennan, D. C. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1218330 · Cited by 1
“The trials were not powered to detect true differences in acute rejection rates, but there were no unexpected changes in rejection rates [19].”
BackgroundEvaluation of Different Initial Doses of Envarsus in De Novo Kidney Transplant Recipients
Más‐Serrano, P., Franco, A., Beltrá‐Picó, I., Díaz-González, M., Colomer, C., Gascón, I., de la Cruz, E., Pérez-Contreras, J., Nalda‐Molina, R., & Ramón-López, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165687 · Cited by 1
“Some studies have included a significant proportion of Black transplant recipients [4,27–29], who may require up to twice the dose of tacrolimus compared to White recipients to achieve similar trough concentrations [30].”
Doyle, I. C., & Malhotra, A. (2015) · Wiley eBooks · doi:10.1002/9781119041412.ch15 · Cited by 1
Khajeh, E., Polychronidis, G., Ramouz, A., Alamdari, P., Murtha-Lemekhova, A., Saracevic, M., Ali‐Hasan‐Al‐Saegh, S., Ghamarnejad, O., Majlesara, A., Dezfouli, S. A., et al. (2020) · Medicine · doi:10.1097/md.0000000000022180 · Cited by 1
“,([16,17]) as well as an improved clinical safety profile.”
BackgroundOptimizing immunosuppressive therapy after renal transplantation
van Boekel, G. A. J. (2015) · Radboud Repository (Radboud University)
Pharmacokinetic challenges in renal replacement therapy
Egeland, E. J. (2019) · NORA - Norwegian Open Research Archives
Vadcharavivad, S., Saengram, W., Phupradit, A., Poolsup, N., & Chancharoenthana, W. (2019) · Drugs · doi:10.1007/s40265-019-01232-8
Coffman, K., Patel, N., Bartlett, F., Newman, J., Patel, S., Sprague, T., Rao, N., Andrade, E., Casey, M. J., Rohan, V., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.14944
Towns, G. C., Agarwal, G., Tamhane, A. R., & Kew, C. E. (2023) · Medical Science Monitor · doi:10.12659/msm.939748
Romine, M. M., Leeser, D. B., Kennamer, K., Nguyen, C., Jones, H., McLawhorn, K. J., Kendrick, S. A., & Irish, W. D. (2024) · Clinical Transplantation · doi:10.1111/ctr.15268
Yang, C.-W., Velez, J. C. Q., & Cohen, D. L. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000541334
Characterizing the Use of Prolonged-Release Once-Daily Tacrolimus (LCPT) across Canada
Phommavong, V., Burger, C., Shamseddin, M. K., & Mansell, H. (2025) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3624
Gul, H. L., Sockolov, M., Howes, K. A., Kaur, A., Occhipinti, M., Bang, H., Alnimri, M., Huang, Y., Dray, J. V., & Chen, L. (2025) · Transplantation Reports · doi:10.1016/j.tpr.2025.100178
Ali, Z. M., Fernández-Alarcón, B., Fontova, P., Vidal‐Alabró, A., Rigo-Bonnin, R. F., Melilli, E., Montero, N., Manonelles, A., Coloma, A., Favà, A., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091185
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation
Vidal‐Alabró, A., Fontova, P., Ali, Z. M., Fernández-Alarcón, B., Cerezo, G., Melilli, E., Montero, N., Coloma, A., Manonelles, A., Favà, A., et al. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001411
Metadata
- Authors
- Gaber, A. O., Alloway, R. R., Bodziak, K., Kaplan, B., & Bunnapradist, S.
- Affiliations
- Houston Methodist (US)
- Christ Hospital (US)
- University of Oklahoma Health Sciences Center (US)
- University of Illinois Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- Gaber, A. Osama
- Venue
- Transplantation
- Published
- 2013-07-27
- Volume
- 96
- Issue
- 2
- Pages
- 191-197
- ISSN
- 0041-1337 (ISSN-L)
- PMC
- PMC3723088
- OpenAlex
- W2089557861
- Cited by
- 100
- References
- 25
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 7 · 2023: 12 · 2022: 3 · 2021: 11 · 2020: 9 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 5
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Transplantation (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Baylor University
- University of Cincinnati
- Veloxis Pharmaceuticals
- University of Illinois at Urbana-Champaign
- University of California, Los Angeles
- Baylor University Medical Center
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- tacrolimus, sustained-release formulation, once-daily dosing, kidney transplant recipients, pharmacokinetics, bioavailability, trough concentration, immunosuppression
- MeSH terms
- Adult, Biological Availability, Capsules, Delayed-Action Preparations, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prospective Studies, Kidney Transplantation, Tacrolimus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


